Multiple myeloma drugs fall into various drug classes, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, corticosteriods, histone deactylase inhibitors (HDACs), bisphophonates, and monoclonal antibodies (MAbs). In this section, a chart breaks down these medications according to their drug class. Also included is a timeline showing when each drug became FDA-approved as well as a guide to the generic, brand, and other alternate names for various drugs.

Drugs in Current Use for Multiple Myeloma

Classes: Mides, Mibs, MAbs and Others to Treat Multiple Myeloma

Drug Class Name Abbreviations Brand
Proteasome inhibitors ixazomib I Ninlaro®
carfilzomib cfz, car, K Kyprolis®
bortezomib btz, bor, V Velcade®
Immunomodulators       pomalidomide pom, P Pomalyst®
lenalidomide len, R Revlimid®
thalidomide thal, T Thalomid®
Alkylating agents melphalan mel, M Alkeran®, Alphalan®
cyclophosphamide       CTX, Cy, C Cytoxan®
bendamustine   Treanda®
Corticosteroids dexamethasone D, d, dex, DXM    Decadron®
prednisone pred, P Delatsone®
methylprednisolone none yet Medrol®
Histone Deactylase Inhibitors     panobinostat none yet Farydak®
Bone-modifying agents denosumab none yet Xgeva®
zoledronic acid zol Zometa®
pamidronate pmd Aredia®
Monoclonal antibodies daratumumab dara Darzalex®
elotuzumab elo, E Empliciti®
XP01 inhibitor selinexor none yet Xpovio®

Myeloma Drug Timeline

multiple myeloma drug development timeline

Guide to Drug Names

GENERIC NAME BRAND NAME ORIGINAL NAME

afuresertib

 

GSK2110183

bendamustine

Treanda®

SDX-105

bortezomib

Velcade®

PS-341

carfilzomib

Kyprolis®

PR-171

cyclophosphamide

Cytoxan®

 

dabrafenib

Tafinlar®

 

daratumumab

Darzalex®

CD38 mAb

dasatinib

Sprycel®

BMS-354825

denosumab

XGEVA®

AMG-162, osteoprotegerin

dinaciclib

 

SCH 727965

durvalumab

 

MED14736

eltrombopag

Promacta®

 

elotuzumab

Empliciti®

HuLuc63

everolimus

Afinitor®

LY317615

filanesib

 

ARRY-520

Ibrutinib

Imbruvica®

PCI-32765

indatuximab ravtansine

 

BT062

ipilumumab

Yervoy®

 

ixazomib

Ninlaro®

MLN9708

lenalidomide

Revlimid®

CC-5013

lirilumab

 

IPH-2102, BMS-986015

marizomib

 

NPI-0052, salinosporamide

masitinib

 

AB1010

melphalan

Alkeran®

 

nelfinavir

Viracept®

 

nivolumab

Opdivo®

BMS-936558

oprozomib

 

ONX-0912

palbociclib

Ibrance®

PD 0332991

pamidronate

Aredia®

 

panobinostat

Farydak®

LBH589

pegylated liposomal doxorubicin

Doxil®

 

pembrolizumab

Keytruda®

MK-3475-013

pidilizumab

 

CT-011

plerixafor

Mozobil®

AMD3100

plitidepsin

Aplidin®

 

pomalidomide

Pomalyst®

CC-4047

quisinostat

 

JNJ26481585

ricolinostat

 

ACY-1215

romidepsin

Istodax®

FK228, depsipeptide

selinexor

Xpovio®

KPT-330

sirolimus

Rapamune®

rapamycin, AY 22989

sonidegib

Odomzo®

LDE225, erismodegib

sotatercept

 

ACE-011

temsirolimus

Torisel®

CCI-779

thalidomide

Thalomid®

 

trametinib

Mekinist®

GSK11202

ulocuplumab

 

BMS-936564

urelumab

 

BMS-663513

venetoclax

Venclexta®

ABT-199

vorinostat

Zolinza®

SAHA

zoledronic acid, zoledronate

Zometa®

 

IMf logo


The International Myeloma Foundation medical and editorial content team

Comprised of leading medical researchers, hematologist/oncologists, oncology-certified nurses, medical editors, and medical journalists, our team has extensive knowledge of the multiple myeloma treatment and care landscape. Additionally, Dr. Brian G.M. Durie reviews and approves all medical content on this website.

Last Medical Review: August 15, 2019

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt out, click for more information.